Bambusa Therapeutics (BBTX) upsized its IPO at pricing to 10.55 million shares – up from 9.38 million shares – and priced the IPO at $16.00 – the mid-point of its range – to raise $168.8 million on Thursday night, Oct. 29, 2026. The Boston biotech’s stock is expected to start trading tomorrow – Friday, Oct. 30 – on the NASDAQ. At pricing, Bambusa Therapeutics had a market cap of about $815.71 million.
BofA Securities, Evercore ISI, UBS Investment Bank and Cantor were the joint book-runners.
Bambusa Therapeutics (BBTX) is a Phase 1/2a biotech targeting atopic dermatitis and COPD.
RA Capital is a principal shareholder.
Bambusa Therapeutics is developing two lead product candidates:
*BBT001 is “designed to simultaneously address core Type 2 inflammation and chronic itch, the two defining burdens of atopic dermatitis (“AD”) and other inflammatory skin diseases,” according to the prospectus.
The company plans to initiate study start-up activities for its Phase 2b dose-ranging clinical trial of a SubQ formulation of BBT001 to treat patients with moderate-to-severe AD (“Phase 2b AD Study”) by the end of 2026.
*BBT002 “has the potential to address a number of Type 2 inflammatory disorders across respiratory and allergic diseases,” Bambusa Therapeutics said in the prospectus.
“We are currently evaluating BBT002 for: (i) the treatment of chronic obstructive pulmonary disease (COPD) in our global Phase 1 clinical trial in the United States, Australia, Europe, Georgia, and New Zealand (“Global BBT002 Study”); and (ii) our Phase 1/2a clinical trial for COPD in China (“China COPD Study”),” Bambusa Therapeutics said in the prospectus. “We are also evaluating BBT002 for the treatment of chronic rhinosinusitis with nasal polyps (“CRSwNP”) in a Phase 2a clinical trial in China (“China CRSwNP Study”).”
Since its inception on March 14, 2024, Bambusa Therapeutics, Inc. has acquired assets from BioNTech (Zhuhai) Pharmaceuticals R&D, a subsidiary of BioNTech then known as Biotheus, and those assets became its lead product candidates, BBT001 and BBT002, the prospectus said.
The Boston biotech also has two preclinical product candidates – BBT003 – for inflammatory bowel diseases (“IBD”) with a plan to start a Phase 1 clinical trial by the end of 2026 – and BBT004 – for autoantibody-driven AID – with a plan to start a Phase 1 clinical trial by the end of 2027, Bambusa Therapeutics said in the prospectus.
Financial Snapshot: Net loss of $48.7 million for the 12 months that ended on June 30, 2026, according to the prospectus.
(For more information, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.